If you are a member of the media and would like more information, please contact us at firstname.lastname@example.org or 905-420-6400
Medical Developments International Limited Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada
(Pickering, Canada and Victoria, Australia 11, September, 2016) Medical Developments International Limited (“MDI”) (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada.
English: Purdue Penthrox Announcement.pdf
HELSINN GROUP SIGNS EXCLUSIVE AGREEMENT WITH PURDUE PHARMA CANADA FOR THE DISTRIBUTION AND LICENSING RIGHTS OF AKYNZEO® (NETUPITANT/PALONOSETRON combo) IN CANADA
Lugano, SWITZERLAND and Pickering, CANADA, April 25, 2016: Helsinn, the Swiss Group focused on building quality cancer care products and Purdue Pharma Canada today announce that they have signed an exclusive agreement for the distribution and licensing of Akynzeo®, the oral fixed combination of netupitant and palonosetron developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Purdue Pharma Canada today announced the appointment of John Sebben as Vice President, Manufacturing Operations
PICKERING, ON, April 11, 2016 /CNW/ - John Sebben has joined Purdue as Vice President, Manufacturing Operations, effective today. John brings to Purdue more than 20 years of Canadian and International supply chain and manufacturing operations leadership experience, having worked at a number of premier companies.
Policy Magazine March/April 2016 - Opinion Editorial 'Prescription Drug Abuse and Canada's Lagging Regulatory Framework' by Dr. Craig Landau, (President and CEO of Purdue Pharma Canada) and Doug Sommerville (Teva Canada Ltd.’s GM)
In Budget 2016, the Trudeau government was true to its campaign word. It will negotiate a new Health Accord with the provinces and territories and invest in mental health, palliative care, vaccination uptake and population health interventions with First Nations communities. However, notably absent was mention of Canada’s National Anti-Drug Strategy which includes tactics to address prescription opioid misuse, abuse and diversion along with the broader utilization of abuse-deterrent/tamper-resistant formulations by pharmaceutical manufacturers. The Canadian heads of two leading innovative and generic pharma companies are of one mind on this issue.
Purdue Pharma Canada Joins the NEOMED Institute As an Industrial Partner
MONTREAL, and PICKERING, ON, March 22, 2016 /CNW/ - Purdue Pharma Canada along with the NEOMED Institute, a public-private organization dedicated to drug discovery and the development of therapeutics up to human proof of concept, today announced that Purdue has become an industrial partner and thereby becomes one of the five leading pharmaceutical companies to support NEOMED's efforts to close the gap between great science and life-saving medicines.
The Hill Times (Monday, March 14, 2016 ) – “Minister Philpott should bring in regs to accelerate use of abuse-deterrent formulations for opioid medications” Opinion Editorial by Dr. Craig Landau, President & CEO, Purdue Pharma Canada https://www.hilltimes.com/2016/03/14/philpott-should-bring-in-regs-to-accelerate-use-of-abuse-deterrent-formulations-for-opioid-medications/53317
Purdue Pharma Canada announces the appointment of Dr. Julie Ducharme as Vice President, Research and Development
PICKERING, ON, Jan. 11, 2016 /CNW/ - Purdue Pharma Canada today announced the appointment of Dr. Julie Ducharme as Vice President, Research and Development.
"Dr. Ducharme is a dynamic leader with a proven track record in clinical research, drug discovery and early drug development both in Canada and internationally." said Dr. Craig Landau, President and CEO of Purdue Pharma. "Her extensive network and her experience in progressing collaborative projects will be key to building a robust product pipeline and to driving Purdue's growth strategy."